Rapid Alert Notification of a Quality Defect / Recall



Similar documents
PROCEDURE FOR HANDLING RAPID ALERTS AND RECALLS ARISING FROM QUALITY DEFECTS

Decentralised Procedure. Public Assessment Report

Working Party on Control of Medicines and Inspections. Final Version of Annex 16 to the EU Guide to Good Manufacturing Practice

Narcotics Ordinance on Charges (Betäubungsmittel-Kostenverordnung) Introductory clause

The RASFF Tasks and Responsibilities of the National Contact Point and the Federal State Contact Points

COMMISSION DIRECTIVE 2003/94/EC

QUALITY SYSTEM REQUIREMENTS FOR PHARMACEUTICAL INSPECTORATES

Compilation of Community Procedures on Inspections and Exchange of Information

Guideline on the Regulation of Therapeutic Products in New Zealand

Guide to The Notification System for Exempt Medicinal Products

Decentralised Procedure. Public Assessment Report. Gadojaco Handvist Gadopentetat Dimeglumin Jacobsen 500 Mikromol/ml Injektionslösung

Decentralised Procedure. Public Assessment Report. Paracetamol-ratiopharm 10 mg/ml Infusionslösung Paracetamol DE/H/1908/001/DC

Compilation of Community Procedures on Inspections and Exchange of Information

The Quality System for Drugs in Germany

EFPIA Good Practice Revision 1, October 2014

Abkürzungen. Anatomisch Therapeutisch Chemischer Code der WHO. Bundesinstitut für Arzneimittel und Medizinprodukte (

EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL. EudraLex. The Rules Governing Medicinal Products in the European Union

Qualified Persons in the Pharmaceutical Industry Code of Practice 2009, updated August 2015

9th DGRA Annual Congress

Recent Updates on European Requirements and what QPs are expected to do

Guidance for Industry: Starting Material Supplier Management

Clinical Trial Logistics

The EFGCP Report on The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2012) Germany

Certification Bodies for Quality Management Systems

The Changing Regulatory Requirements for Applied Human Pharmacology. Thomas Sudhop Federal Institute for Drugs and Medical Devices (BfArM)

Guidance for Handling Defective Medicinal Products

SADC GUIDELINES ON IMPORT AND EXPORT PROCEDURES FOR PHARMACEUTICAL PRODUCTS

A critical review of the current. marketing authorisation transfer procedure. in Europe

155 McDonald Drive SW Shirley E. Charette, MS, PA-C

RECOMMENDATION ON THE CONTENT OF THE TRIAL MASTER FILE AND ARCHIVING

MACROGOL COMPOUND ORAL POWDER (sodium chloride, sodium hydrogen carbonate, potassium chloride, macrogol 3350) PL 33579/0001 UKPAR TABLE OF CONTENTS

PROPOSED UPDATED TEXT FOR WHO GOOD MANUFACTURING PRACTICES FOR PHARMACEUTICAL PRODUCTS: MAIN PRINCIPLES (JANUARY 2013)

Risk Management and Crisis Coordination

Privacy Notice Document (HIPAA)

Important safety notice: corrective measure to a medical device on the market MEDUMAT Transport: modification to device software

Professional Standards and Guidance for the Sale and Supply of Medicines

How To Understand Your Role In A Pharmacy

CHAPTER 15 MEDICINAL PRODUCTS GMP INSPECTION AND BATCH CERTIFICATION

Omeprazole 20 mg gastro-resistant tablets PL 14017/0277

Update: Proposed Medical Device Regulation (MDR) & IVD Regulation (IVDR)

How companies leverage quality and quality certifications to achieve competitive advantage

Managing challenges in early drug development: Biologicals and small molecules

A European Medicines Verification System

GMP Issues for Start-Ups, quality in the supply chain and role of the Qualified Person (QP)

EUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY VERSION 7

Memantine hydrochloride 20 mg film-coated tablets PL 17907/0291

Guidance notes. for Patient Safety and Pharmacovigilance in Patient Support Programmes

20-21 May 2015, Lisbon, Portugal. Highlights. Speakers:

Guideline on dossier requirements for Type IA and IB notifications

Self-Audit Checklist

New Guidelines on Good Distribution Practice of Medicinal Products for Human Use (2013/C 68/01)

Questions & answers on signal management

EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL VERSION 4.1

MUTUAL RECOGNITION PROCEDURE DECENTRALISED PROCEDURE PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT

Guideline on good pharmacovigilance practices (GVP)

STANDARD OPERATING PROCEDURE FOR RESEARCH. 2. Notification of Serious Breaches of Good Clinical Practice or Study Protocol

Mandatory Quality Assurance in the German Health Care System

PL 17871/0208 UKPAR TABLE OF CONTENTS

How To Inspect A Blood Bank

HIPAA-ACKNOWLEDGEMENT OF RECEIPT Notice of Privacy Practices

PATIENT REGISTRATION FORM

Track & Trace. The Distribution Chain to the EU and within the EU

RAPID ALERT SYSTEM (RAS) IN PHARMACOVIGILANCE

Article 29 Working Party Issues Opinion on Cloud Computing

River Valley Therapy & Sports Medicine, Inc. Notice of Privacy Practices

PRIVACY NOTICE. In certain situations, we may also disclose patient information to another provider or health plan for their health care operations.

Northwest Cardiology Associates 400 W. Northwest Hwy Barrington, IL Fax HIPAA Notice of Privacy Practices ( Notice )

Montelukast 10mg film-coated tablets PL 17907/0474

Wellness Consultation Policies. HIPAA Notice of Privacy Practices

REGULATION (EEC) No 2309/93

SAP Splash Privacy Statement

Conformity assessment procedures of breast implants

NOTICE OF PRIVACY PRACTICES

EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL

Donepezil hydrochloride 10 mg film-coated tablets PL 19156/0130

HMPWG in the view of the NCA

Beclometasone Dipropionate 50 micrograms per spray Aqueous Nasal Spray PL 16431/0178

Guide to Distribution of Cosmetic Products in Ireland

Annex 9 Guide to good storage practices for pharmaceuticals 1

Public Assessment Report. Decentralised Procedure

STATUTORY INSTRUMENTS. S.I. No. 336 of 2011

Regulations for Shareholders Safekeeping Accounts at Swiss Life

Temporary Authorisations for Use (ATU)

EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL

1. Scope of Agreement 1.1 TMG will sell to the Customer the Products defined in an individual agreement between TMG and the Customer.

Protected Health Information. Notice Information. Notice of Privacy Practices. Nystrom & Associates, Ltd Family Support Services, Inc.

3.Prescriber DEA: 4.Board Registration Number: 5.Business Tel:

Author General Management Quality Assurance

China is getting healthy- What s in for me?

Transcription:

DRINGEND - BITTE SOFORT AUSLIEFERN! IMPORTANT - DELIVER IMMEDIATELY Rapid Alert Notification of a Quality Defect / Recall Meldende Stelle Landesamt für soziale Dienste Schleswig-Holstein, Abt. Gesundheitsschutz State Social Services Agency of Land Schleswig-Holstein, Department of Healthcare 1. To / Empfänger: FAX Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) 0228-207-3515 Bundesamt für Verbraucherschutz und Lebensmittelsicherheit (BVL) 01888/412-2303 Paul-Ehrlich-Institut - Bundesamt für Sera und Impfstoffe - (PEI) 06103/77-1234 Oberste Landesgesundheitsbehörde (Ministerium für Soziales, Gesundheit, Familie, Jugend und Senioren of Land Schleswig- Holstein) 0431/988-5416 2. Product Recall Class of Defect: I (circle one) 4. Product: Heparin-Rotexmedica solution for injection 3. Counterfeit / Fraud (specify)* --- 5. Marketing Authorisation Number: * For use in humans/animals (delete as required) 6391377.00.00 6. Brand/Trade Name: 7. INN or Generic Name: Heparin-Rotexmedica Heparin-Natrium 8. Dosage Form: 9. Strength: solution for injection 5.000 I.E./ml 10. Batch/Lot Number: 11. Expiry Date: 70067, 70099, 70100, 70449, 70512 05/2010, 05/2011, 05/2011, 04/2012, 06/2012 12. Pack size and Presentation: 13. Date Manufactured: * all sizes 11.07.07, 14.06.07, 14.06.07, 25.05.07, 11.07.07 14. Marketing Authorisation Holder: *,,

15. Manufacturer : 16. Recalling Firm (if different): 17. Recall Number Assigned (if available) --- 18. Details of Defect/Reason for Recall: In addition to our Rapid Alert Notification dated 05.03.2008 and our follow-up report dated 07.03.2008 we inform you that five further medicinal product batches (70067, 70099, 70100, 70449, 70512) of Rotexmedica GmbH have been identified to also contain the API batch 447012302M, manufactured by Changzhou Quianhong Bio Pharma Co. Ltd., China. The connection to the quality of API heparin-natrium is still unclear. For reasons of precaution these batches have also to be recalled. 19. Information on distribution including exports (type of customer, e.g. hospitals): * 70067: Feparvi, Panpharma; 70099, 70100: Feparvi; 70449: Germany; 70512: Germany. 20. Action taken by Issuing Authority: Order of recall 21. Proposed Action: The German authorities are requested to investigate the source of the API heparin at the marketing authorization holders. Hospital pharmacies should withdraw the respective batches from their hospitals. 22. From (Issuing Authority): Landesamt für soziale Dienste Schleswig-Holstein, Abt. Gesundheitsschutz State Social Services Agency of Land Schleswig-Holstein, Department of Healthcare 23. Contact Person: Silke Frick-Salzwedel Telephone: +49 (0)431 988-5656 24. Signed: 25. Date: 10.03.2008 26. Time: * 18.10 h * Information not required, when notified from outside EU.

The holder of an authorisation referred to under Article 40 of Directive 2001/83/EC or Article 44 of Directive 2001/82/EC and the holder of the authorisation on behalf of whom the Qualified Person has released the batch in accordance with Article 51 of Directive 2001/83/EC or Article 55 of Directive 2001/82/EC if different. This is intended only for the use of the party to whom it is addressed and may contain information that is privileged, confidential, and protected from disclosure under applicable law. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please notify us by telephone immediately and return it to us at the above address by mail. Thank you

DRINGEND - BITTE SOFORT AUSLIEFERN! IMPORTANT - DELIVER IMMEDIATELY Rapid Alert Notification of a Quality Defect / Recall Meldende Stelle Landesamt für soziale Dienste Schleswig-Holstein, Abt. Gesundheitsschutz State Social Services Agency of Land Schleswig-Holstein, Department of Healthcare 1. To / Empfänger: FAX Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) 0228-207-3515 Bundesamt für Verbraucherschutz und Lebensmittelsicherheit (BVL) 01888/412-2303 Paul-Ehrlich-Institut - Bundesamt für Sera und Impfstoffe - (PEI) 06103/77-1234 Oberste Landesgesundheitsbehörde (Ministerium für Soziales, Gesundheit, Familie, Jugend und Senioren of Land Schleswig- Holstein) 0431/988-5416 2. Product Recall Class of Defect: I (circle one) 4. Product: Heparin-Rotexmedica solution for injection 3. Counterfeit / Fraud (specify)* --- 5. Marketing Authorisation Number: * For use in humans/animals (delete as required) --- 6. Brand/Trade Name: 7. INN or Generic Name: Heparin-Rotexmedica Heparin-Natrium 8. Dosage Form: 9. Strength: solution for injection 5.000 I.E./ml 10. Batch/Lot Number: 11. Expiry Date: 70701 11/2011 80140 01/2011 (Pakistan), 01/2013 (Vietnam) 12. Pack size and Presentation: 13. Date Manufactured: * all sizes 19.12.2007, 19.02.2008 14. Marketing Authorisation Holder: *,,

15. Manufacturer : 16. Recalling Firm (if different): 17. Recall Number Assigned (if available) --- 18. Details of Defect/Reason for Recall: In addition to our Rapid Alert Notifications dated 05.03.2008 and 10.03.2008 we inform you that two further medicinal product batches (70701, 80140) of Rotexmedica GmbH contain another API batch of Yantai Dongcheng Biochemicals Co., Ltd., China, which is named DHS070705. Rotexmedica GmbH, who additionally to State Social Services Agency Schleswig-Holstein has performed laboratory tests, has noticed that this API batch DHS 070705 has shown the same 1H-NMR-result as API batch DHS 070603. DHS 070603 was used for manufacturing the concerned medicinal product batches 70699 and 70587 as we have informed you already in our first Rapid Alert Notification dated 05.03.2008. The 1H-NMRresult of both API batches is strongly different from the currently published FDA-standard. A causal link between the adverse events respectively the notified clotting problems during dialysis and the stated deviation in 1H-NMR has not been established at the moment. For reasons of precaution Rotexmedica GmbH has decided to recall the above mentioned medicinal product batches. 19. Information on distribution including exports (type of customer, e.g. hospitals): * Only export! Rotexmedica GmbH has already contacted the following firms: 70701: Laboratorios Feparvi Ltda., Calle 70 No. 4-50, Santafe de Bogota, Columbia 80140: Haji Medicine Co., B/327, Iqbal Road, Rawalpindi, Pakistan (Imports, Distributions) 80140: CPC NO.1, KM 6 GIAI PHONG STREET, DONG DA-HANOI, Vietnam (Central Pharmaceutical Company) 20. Action taken by Issuing Authority: Investigations, e.g. laboratory testing, to find the reason for the adverse events. 21. Proposed Action: The German Authorities should inspect whether there are other companies in Germany which have received the also suspected API batch DHS070705 from Yantai Dongcheng Biochemicals Co., Ltd., China.

22. From (Issuing Authority): Landesamt für soziale Dienste Schleswig-Holstein, Abt. Gesundheitsschutz State Social Services Agency of Land Schleswig-Holstein, Department of Healthcare 23. Contact Person: Silke Frick-Salzwedel Telephone: +49 (0)431 988-5656 24. Signed: 25. Date: 14.03.2008 26. Time: * 9.00 h * Information not required, when notified from outside EU. The holder of an authorisation referred to under Article 40 of Directive 2001/83/EC or Article 44 of Directive 2001/82/EC and the holder of the authorisation on behalf of whom the Qualified Person has released the batch in accordance with Article 51 of Directive 2001/83/EC or Article 55 of Directive 2001/82/EC if different. This is intended only for the use of the party to whom it is addressed and may contain information that is privileged, confidential, and protected from disclosure under applicable law. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please notify us by telephone immediately and return it to us at the above address by mail. Thank you